Review Series on Myeloproliferative Neoplasms

About this episode

Dr. Jason Gotlib discusses advances in targeted therapeutics for myeloproliferative neoplasms with expert guests.

In this episode, Blood Associate Editor Dr. Jason Gotlib discusses the Review Series " The New Wave of Targeted Therapeutics for MPN’s ", with authors Drs. Stefan Constantinescu, Ann Mullally, and Marina Kremyanskaya. This Review Series covers 3 areas where exciting advances are occurring. Dr. Constantinescu discusses “ Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms ” which describes how new ways to switch off JAK signaling are delivering a suite of new small-molecule drugs with potential. Dr. Mullally discusses “ Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis ” which reviews the biology of calreticulin mutations in myelofibrosis and ET and how multiple different modalities can be brought to bear against this mutant surface protein, including monoclonal antibodies, bispecific T-cell engagers, and cellular and vaccine therapies. Dr. Kremyanskaya discusses “ Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis ” which outlines the major recent progress being made in controlling excessive erythropoiesis through pharmacological modulation of iron metabolism.

People in this episode

Host: Dr. Jason Gotlib

Guests: Dr. Stefan Constantinescu, Dr. Ann Mullally, Dr. Marina Kremyanskaya

Topics covered

• myeloproliferative neoplasms
• targeted therapeutics
• JAK inhibitors
• calreticulin mutations
• erythropoiesis
• iron metabolism

Keywords

• myeloproliferative neoplasms
• JAK inhibitors
• calreticulin
• essential thrombocythemia
• myelofibrosis
• erythropoiesis
• iron metabolism

Mentioned in this episode

Books & works: The New Wave of Targeted Therapeutics for MPN’s, Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms, Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis, Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis

More episodes of Blood Podcast

• Future Directions in Relapsed and Refractory Large B-cell Lymphoma · June 11, 2026 · 25 min
• Review Series on Clonal Tracking in Hematopoiesis · June 4, 2026 · 30 min
• New Approaches: Marstacimab Therapy and HLH Biomarkers · May 28, 2026 · 18 min
• Review Series on Hemophagocytic Lymphohistiocytosis (HLH) · May 21, 2026 · 16 min
• IBD augmentation of CHIP and Platelet mTOR's impact on Cerebral Malaria · May 14, 2026 · 21 min
• Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia · May 7, 2026 · 13 min